|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000037422 |
|
Date of registration:
|
01/08/2019 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease
|
|
Scientific title:
|
An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease |
|
Date of first enrolment:
|
2019/08/01 |
|
Target sample size:
|
25 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042659 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Masahiro
Kanai |
|
Address:
|
1, Kaimei-hira, Ichinomiya-city, Aichi, 494-0001, Japan
494-0001
Japan |
|
Telephone:
|
0586480077 |
|
Email:
|
masabilliard35@yahoo.co.jp |
|
Affiliation:
|
Ichinomiya Nishi Hospital Neurology |
|
|
Name:
|
Masahiro
Kanai |
|
Address:
|
1, Kaimei-hira, Ichinomiya-city, Aichi, 494-0001, Japan
Japan |
|
Telephone:
|
0586480077 |
|
Email:
|
masabilliard35@yahoo.co.jp |
|
Affiliation:
|
Ichinomiya Nishi Hospital Neurology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1. Istradefylline has been prescribed. 2. The patient can not stand. 3. The angle of camptocormia is less than 10 degrees.
Age minimum:
40years-old
Age maximum:
85years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Parkinson disease
|
|
Intervention(s)
|
|
Prescription istradefylline 20 mg for 1 month, and if there are no side effects, increase to 40 mg and prescribe for 2 months.
|
|
Primary Outcome(s)
|
|
Primary outcome is the angle of camptocormia
|
|
Secondary Outcome(s)
|
|
Secondary outcomes are Movement Disorder Society-Unified Parkinson Disease Rating Scale(MDS-UPDRS), Non-motor symptoms scales.
|
|
Source(s) of Monetary Support
|
|
none
|
|
Ethics review
|
Status: YES
Approval date: 15/02/2019
Contact:
matsubara@anzu.or.jp
Ichinomiya Nishi Hospital
0586480077
matsubara@anzu.or.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
01/08/2021 |
|
URL:
|
|
|
|